Michael Puckette

The spread of African Swine Fever (ASF) across much of the world is a profound challenge to both domestic and wild Suidae populations. While vaccine and countermeasure development for domestic swine are ongoing, the understanding of ASF within wildlife is limited. This gap in knowledge is largely due to the requirements of working with African Swine Fever Virus (ASFV) in high containment laboratories, the complexity of utilizing wildlife in these settings, and researcher access to non-native species. Researching the role of ASFV within wildlife primary cells, outside a vivarium, is currently limited by the need to utilize either terminal processing procedures, such as harvesting alveolar macrophages or bone marrow, or processes requiring large volumes of blood, such as peripheral blood mononuclear cell harvests. The limited availability and access restrictions of susceptible wildlife makes obtaining these samples difficult, especially when working with endangered wildlife species. Harvesting buffy coat fractions is independent of terminal methodologies and the need for large volumes of blood. A methodology to support ASFV replication has recently been demonstrated utilizing domestic swine blood derived buffy coat cells. Through establishing collaborations with zoological partners, we apply this methodology to small volumes of blood from an African Warthog, a known ASF susceptible species. These results demonstrate the value of such partnerships and how they may be utilized in the future to evaluate ASFV in wildlife derived cells in vitro.

African swine fever (ASF) has emerged as a preeminent threat to worldwide pork production. Research and diagnostics of ASF virus (ASFV) is dependent upon culturing virus in primary cells, such as peripheral blood macrophages (PBMC) derived from swine blood, or pulmonary alveolar macrophages (PAM) extracted from swine lungs. The methodologies for production of these cells can be laborious, requiring significant investment in vivarium, personnel, and technical resources. As an alternative, the buffy coat cell fraction from blood contains a mixture of cell types, including undifferentiated monocytes that can be easily isolated by centrifugation. Herein, we culture buffy coat cells in macrophage (M∅) base media, containing L929 conditioned media to induce monocyte differentiation and enhance sensitivity to ASFV. Culturing the buffy coat cell fraction in M∅ base media enhanced the abundance of rosettes and number of detectable ASFV genome copies relative to buffy coat cells grown without L929 conditioned media. Buffy coat fraction cells were used to propagate ASFV directly from blood of infected swine and subsequent sequencing of extracted viral DNA yielded full genome coverage and identification of point mutations. This work demonstrated that growing ASFV in cells of the buffy coat fraction for pig blood was an effective alternative to using the traditionally isolated primary cell types for ASFV propagation, isolation, and sequencing.

We evaluated four DNA vaccine candidates for their ability to produce virus-like particles (VLPs) and elicit a protective immune response against Foot-and-mouth disease virus (FMDV) in cattle. Two traditional DNA plasmids and two DNA minicircle constructs were evaluated. Both the pTarget O1P1-3C plasmid and O1P1-3C minicircle encoded a wild-type FMDV 3C protease to process the P1-2A polypeptide, whereas the O1P1-HIV-3C^T minicircle used an HIV-1 ribosomal frameshift to down-regulate expression of a mutant 3C protease. A modified pTarget plasmid with a reduced backbone size, mpTarget O1P1-3C^LT, used a 3C protease containing two mutations reported to enhance expression. All constructs produced mature FMDV P1 cleavage products in transfected cells, as seen by western blot analysis. Three constructs, O1P1-3C minicircles, pTarget O1P1-3C, and mpTarget O1P1-3C^LT plasmids, produced intracellular VLP crystalline arrays detected by electron microscopy. Despite VLP formation in vitro, none of the DNA vaccine candidates elicited protection from clinical disease when administered independently. Administration of pTarget O1P1-3C plasmid enhanced neutralizing antibody titers when used as a priming dose prior to administration of a conditionally licensed adenovirus-vectored FMD vaccine. Further work is needed to develop these DNA plasmid-based constructs into standalone FMD vaccines in cattle.

To improve the production of foot-and-mouth disease (FMD) molecular vaccines, we sought to understand the effects of the FMD virus (FMDV) 2B viroporin in an experimental, plasmid-based, virus-like particle (VLP) vaccine. Inclusion of the FMDV viroporin 2B into the human Adenovirus 5 vectored FMD vaccine enhanced transgene expression despite independent 2B expression negatively affecting cell viability. Evaluating both wildtype 2B and mutants with disrupted viroporin activity, we confirmed that viroporin activity is detrimental to overall transgene expression when expressed independently. However, the incorporation of 2B into an FMD molecular vaccine construct containing a wildtype FMDV 3C protease, a viral encoded protease responsible for processing structural proteins, resulted in enhancement of transgene expression, validating previous observations. This benefit to transgene expression was negated when using the FMDV 3C^L127P mutant, which has reduced processing of host cellular proteins, a reversion resulting from 2B viroporin activity. Inclusion of 2B into VLP production constructs also adversely impacted antigen extraction, a possible side effect of 2B-dependent rearrangement of cellular membranes. These results demonstrate that inclusion of 2B enhanced transgene expression when a wildtype 3C protease is present but was detrimental to transgene expression with the 3C^L127P mutant. This has implications for future molecular FMD vaccine constructs, which may utilize mutant FMDV 3C proteases.

Senecavirus A (SVA) is a member of the family Picornaviridae and enzootic in domestic swine. SVA can induce vesicular lesions that are clinically indistinguishable from Foot-and-mouth disease, a major cause of global trade barriers and agricultural productivity losses worldwide. The LF-BK α_Vβ₆ cell line is a porcine-derived cell line transformed to stably express an α_Vβ₆ bovine integrin and primarily used for enhanced propagation of Foot-and-mouth disease virus (FMDV). Due to the high biosecurity requirements for working with FMDV, SVA has been considered as a surrogate virus to test and evaluate new technologies and countermeasures. Herein we conducted a series of comparative evaluation in vitro studies between SVA and FMDV using the LF-BK α_Vβ₆ cell line. These include utilization of LF-BK α_Vβ₆ cells for field virus isolation, production of high virus titers, and evaluating serological reactivity and virus susceptibility to porcine type I interferons. These four methodologies utilizing LF-BK α_Vβ₆ cells were applicable to research with SVA and results support the current use of SVA as a surrogate for FMDV.

RNA viruses, such as foot-and-mouth disease virus (FMDV), have error-prone replication resulting in the continuous emergence of new viral strains capable of evading current vaccine coverage. Vaccine formulations must be regularly updated, which is both costly and technically challenging for many vaccine platforms. In this report, we describe a plasmid-based virus-like particle (VLP) production platform utilizing transiently transfected mammalian cell cultures that combines both the rapid response adaptability of nucleic-acid-based vaccines with the ability to produce intact capsid epitopes required for immunity. Formulated vaccines which employed this platform conferred complete protection from clinical foot-and-mouth disease in both swine and cattle. This novel platform can be quickly adapted to new viral strains and serotypes through targeted exchanges of only the FMDV capsid polypeptide nucleic acid sequences, from which processed structural capsid proteins are derived. This platform obviates the need for high biocontainment manufacturing facilities to produce inactivated whole-virus vaccines from infected mammalian cell cultures, which requires upstream expansion and downstream concentration of large quantities of live virulent viruses.

Background: Type I interferons are widely used in research applications and as biotherapeutics. Current assays used to measure interferon concentrations, such as plaque reduction assays and ELISA, are expensive, technically challenging, and may take days to provide results. We sought to develop a robust and rapid assay to determine interferon concentrations produced from transiently transfected cell cultures. Method: Indirect quantification of recombinant interferon was evaluated using a novel bi-cistronic construct encoding the Foot-and-mouth disease virus 2A translational interrupter sequence to yield equimolar expression of Gaussia princeps luciferase and porcine interferon α. Direct quantification was evaluated by expression of a novel fusion protein comprised of Gaussia princeps luciferase and porcine type I interferon. Plasmids encoding constructs are transiently transfected into cell cultures and supernatant harvested for testing of luminescence, ELISA determined concentration, and anti-viral activity against vesicular stomatitis virus. Results: Bi-cistronic constructs, utilized for indirect quantification, demonstrate both luciferase activity and anti-viral activity. Fusion proteins, utilized for direct quantification, retained secretion and luminescence however only the interferon α fusion protein had antiviral activity comparable to wildtype porcine interferon α. A strong linear correlation was observed between dilution and luminescence for all compounds over a dynamic range of concentrations. Conclusion: The correlation of antiviral and luciferase activities demonstrated the utility of this approach, both direct and indirect, to rapidly determine recombinant interferon concentrations. Concentration can be determined over a more dynamic concentration range than available ELISA based assays using this methodology.

African Swine Fever (ASF) has emerged as a major threat to domestic and wild suid populations, and its continued spread threatens commercial swine production worldwide. The causative agent of ASF, African Swine Fever Virus (ASFV), possesses a linear, double stranded DNA genome. Traditional detection of ASFV relies on laboratory-based virus isolation or real time PCR of samples, typically blood or spleen, obtained from suspect cases. While effective, these methodologies are not easily field deployable, a major limitation during disease outbreak and response management scenarios. In this report, we evaluated the MatMaCorp Solas 8® ASFV detection system, a field deployable DNA extraction and fluorescent detection device, for its ability to extract and detect ASFV from multiple sample types obtained from domestic swine experimentally infected with ASFV strain Georgia. We found that the MatMaCorp Solas 8® ASFV detection device, and affiliated MagicTip™ DNA extraction and C-SAND™ assay kits, readily detected ASFV in blood and spleen, as well as other sample types, including pinna, liver, skin, muscle, and bone marrow. This article is protected by copyright. All rights reserved